In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Turing Pharmaceuticals AG

www.turingpharma.com

Latest From Turing Pharmaceuticals AG

Bookmark
  • Analysis

Drug Pricing Hearing Takes A Partisan Turn As Gilead’s O’Day Holds His Own

By Cathy Kelly
Republicans took off the gloves at House oversight hearing on PrEP, arguing Democrats are more interested in scoring political points than seeking policy solutions to high drug costs.
Pricing Debate Legislation
Bookmark
  • Analysis

The Return Of The “Specialty” Drug Pricing Debate In The US

By Michael McCaughan
Pharma has been almost wholly successful in shifting the ground in the US drug pricing debate away from high-cost “specialty” products and towards the large gap between list and net prices, with the most intense focus on older medicines like insulin. What happens when the debate shifts back?
Pricing Debate Reimbursement
Bookmark
  • Opinion

Pharma Tweeting: Five Twitter Moments That Highlight The Perils Of The Platform

By Anju Ghangurde

Scrip takes a broad look at some controversial Twitter moments that pharma should be watchful of  - words once let out of the cage cannot be whistled back again.

Leadership Strategy
Bookmark
  • Analysis

Drug Pricing And The Trump Effect: How To Make A High Profile Hearing Vanish

By Michael McCaughan

Without President Trump’s focus on drug pricing, it is hard to imagine that seven top industry executives would have had to face a grilling in the US Senate Finance Committee. But they can also thank Trump’s indiscretions for helping ensure that the hearing was barely even a one-day story.

 

Pricing Debate Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Turing Pharmaceuticals LLC
  • Turing Pharmaceuticals LLC
  • Turing Pharmaceuticals LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Turing Pharmaceuticals AG
  • Senior Management
  • Ron Tilles, Interim CEO
    Nancy Retzlaff, Chief Commercial Officer
    Eliseo Oreste Salinas, MD, Pres., R&D
  • Contact Info
  • Turing Pharmaceuticals AG
    Phone: 41 760 24 24
    Haldenstrasse 5
    Baar, NY CH-6340
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By